The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

To determine whether the oscillating clinical response to levodopa in Parkinson's disease (the "on-off" phenomenon) reflects fluctuations in absorption and transport of the drug, we investigated this phenomenon in nine patients with an oscillating motor state. We studied the response to continuous infusion of levodopa and the effects of meals on the plasma levodopa concentrations and on the clinical response during oral and intravenous administration of the drug. Meals reduced peak plasma levodopa concentrations by 29 per cent and delayed absorption by 34 minutes. Bypassing absorption by constant infusion of the drug produced a stable clinical state lasting for 12 hours in all of six patients and for up to 36 hours in some. High-protein meals or oral phenylalanine, leucine, or isoleucine (100 mg per kilogram of body weight) reversed the therapeutic effect of infused levodopa without reducing plasma levodopa concentrations. Glycine and lysine at identical doses had no effect. We conclude that interference with absorption of levodopa by food and by competition between large neutral amino acids and levodopa for transport from plasma to the brain may be partly responsible for the fluctuating clinical response in patients with Parkinson's disease.

[1]  A. Grace,et al.  STRIATAL MODULATION OF DOPAMINE NEURON FIRING , 1984 .

[2]  M. Mena,et al.  Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method , 1984, Acta neurologica Scandinavica.

[3]  P. Ballard,et al.  Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[4]  J. D. de Yébenes,et al.  Effects of 3‐OM‐dopa on monoarnine metabolism in rat brain , 1983, Neurology.

[5]  M. Yahr,et al.  CHOLINERGIC AND DOPAMINERGIC MECHANISMS IN PARKINSON'S DISEASE AFTER LONG TERM LEVODOPA ADMINISTRATION , 1982, The Lancet.

[6]  C. Marsden,et al.  COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.

[7]  S. Fahn,et al.  3‐O‐Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway , 1982, Neurology.

[8]  M. Mena,et al.  [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)]. , 1982, Medicina clinica.

[9]  J. Izzo,et al.  Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. , 1981, Life sciences.

[10]  A. Sved,et al.  Dietary protein intake influences the antihypertensive potency of methyldopa in spontaneously hypertensive rats. , 1980, The Journal of pharmacology and experimental therapeutics.

[11]  P. Kissinger,et al.  DETERMINATION OF CATECHOLAMINES IN RAT BRAIN PARTS BY REVERSE‐PHASE ION‐PAIR LIQUID CHROMATOGRAPHY , 1978, Journal of neurochemistry.

[12]  F. Zavisca,et al.  Effects of neutral amino acids on the antihypertensive action of methyldopa in spontaneously hypertensive rats , 1978, The Journal of pharmacy and pharmacology.

[13]  A. Lieberman,et al.  Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease , 1978, Neurology.

[14]  W. Weiner,et al.  Levodopa‐Induced dopamine receptor hypersensitivity , 1977, Transactions of the American Neurological Association.

[15]  J. Perret,et al.  DOES O‐METHYL‐DOPA PLAY A ROLE IN LEVODOPA‐INDUCED DYSKINESIAS? , 1977, Acta neurologica Scandinavica.

[16]  M. Muenter,et al.  Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.

[17]  C. Marsden,et al.  Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. , 1977, Journal of neurology, neurosurgery, and psychiatry.

[18]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[19]  P. M. Daniel,et al.  DO CHANGES IN BLOOD LEVELS OF OTHER AROMATIC AMINOACIDS INFLUENCE LEVODOPA THERAPY? , 1976, The Lancet.

[20]  I. Shoulson,et al.  On‐off response , 1975, Neurology.

[21]  R. Katzman.,et al.  SYNTHETIC AMINO ACIDS AND THE NATURE OF l‐DOPA TRANSPORT AT THE BLOOD‐BRAIN BARRIER , 1975, Journal of neurochemistry.

[22]  R. Katzman.,et al.  3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier , 1975 .

[23]  W. E. Martin,et al.  Patterns of clinical response and plasma dopa levels in Parkinson's disease , 1975, Neurology.

[24]  S. Fahn.  “On‐off” phenomenon with levodopa therapy in parkinsonism , 1974, Neurology.

[25]  D J Birkett,et al.  Variability of L-dopa absorption in man. , 1974, Australian and New Zealand journal of medicine.

[26]  W. H. Lawrence,et al.  Injected apomorphine and orally administered levodopa in Parkinsonism. , 1972, Archives of neurology.

[27]  R. Wurtman,et al.  Brain Serotonin Content: Physiological Regulation by Plasma Neutral Amino Acids , 1972, Science.

[28]  W H Oldendorf,et al.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.

[29]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[30]  A. Carlsson.  The "on-off" effect. , 1974, Advances in neurology.

[31]  Duvoisin Rc.  Variations in the "on-off" phenomenon. , 1974 .